Change in the spectrum of RET mutations diagnosed between 1994 and 2006

Clinical Laboratory

Volumn 53, Issue 5-6, 2007, Pages 273-282

  Frank Raue, Karin ^a   Rondot, Susanne ^a   Schulze, Egbert ^a   Raue, Friedhelm ^a  

^a Endokrinologische Gemeinschaftspraxis   (Germany)

Author keywords

Medullary thyroid carcinoma; MEN type 2; MTC; Multiple endocrine neoplasia type 2; RET proto oncogene

Indexed keywords

CALCITONIN; GENOMIC DNA; PENTAGASTRIN; PROTEIN RET;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GROWTH; CODON; DNA EXTRACTION; EXON; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE INSERTION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PEDIGREE ANALYSIS; PHENOTYPE; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 34250805935     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Clinical features and screening. Endocr Metabol Clinics North Am 1994;23:137-156.
2. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 1993;363:458-469.
3. Donis-Keller H, Don S, Chi D, Carlson KM, Toshiama K, Lairmore TG, Howe JR, Moley JF, Goodfellow P, Wells SA Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 1993;2:851-856.
4. Wells SA, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA, Donis-Keller H. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Annals Surgery 1994;220:237-250.
5. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel, HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold, M, Komminoth P, Hendy GN, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 1996;276:1575-9.
6. Brandi ML, Gagel R, Angeli A, Bilezikian J, Beck-Peccoz P, Bordi C, Conte-Devotx B, Falchetti A, Gheri R, Libroia A, Lips C, Lombardi G, Manelli M, Pacini F, Ponder B, Raue F, Skogseid B, Tamburrano G, Thakker R, Thompson N, Tomasetti P, Tonelli F, Wells S, Marx S. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671.
7. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven T, Roeher H, Wahl R, Lamesch P, Raue F, Conte-Devolx B, Dralle H. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
8. Yip L, Cote GL, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Archives of Surgery 2003;138:409-416.
9. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15:531-544.
10. Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoiur GM, and the GETC. RET proto-oncogene mutations in French MEN 2A and FMTC families. Human Molecular Genetics 1994;3:1939-1943.
11. Frank-Raue K, Rondot S, Höppner W, Goretzki P, Raue F, Meng W. Coincidence of multiple endocrine neoplasia type 1 and 2: mutations in the RET proto-oncogene and MEN 1 tumor suppessor gene in a family presenting with recurrent primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:4063-4067.
12. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber S, Rondot S, Höppner W, Raue F. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 2006;155:229-236.
13. Colombo-Benkmann M, Frank-Raue K, Groß U, Riemann B, Hengst K, Herbst H, Rondot S, Keuser R, Raue F, Senninger N. Genotype-phenotype correlation of a novel extracellular non-cysteine mutation of the RET protooncogene. J Int Med 2004; 255: 711 (abstact).
14. Machens A, Schneyer U, Holzhausen HJ, Raue F, Dralle H. Emergence of medullary thyroid carcinoma in a family with Cys630Arg RET germline mutation. Surgery 2004;136:1083-1087.
15. Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F. Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 1996;81:1780-3.
16. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature genet 1994;6:70-4.
17. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Hoppner W. A new hot spot for mutations in the RET protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia. type 2A. J Clin Endocrinol Metab 1998;83:770-4.
18. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B, and the GETC. Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotypegenotype relationship in a large series of patients. J Clin Endocrinol Metab 2001;86:3746-3753.
19. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Zakai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder B, Eng C. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Int Med 1995:238:343-346.
20. Dvorakova S, Vaclavikova E, Duskova J, Vlcek P, Ryska A, Bendlova B. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germline mutation Gly321Arg. J Endocrinol Invest 2005; 28:905-909.
21. Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:5438-43.
22. Eng C, Mulligan LM, Smith DP, Healy CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA. Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 1995;43:123-127.
23. Frank-Raue K, Heimbach C, Rondot S, Usadel KH, Meng W, Varma C, Fuchs-Hammoser R, Hoppner W, Schulze E, Raue F. Hereditäres medulläres Schilddrüsenkarzinom-Genotyp-Phänotyp-Charakterisierung. Dtsch Med Wochenschr 2003;128:1998-2002.
24. Feldmann GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Robertson J, Petrucelli N, Jackson CE. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to RET V804M (GTG-ATG) mutation. Surgery 2000;128:93-98.
25. Vierhapper H, Bieglmayer C, Heinze G, Baumgartner-Parzer S. Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 2004;14:580-583.
26. Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, Hüfner M, Niederle B, Brabant G. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004;112:52-58.
27. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet. 1998; 7:129-34.
28. Kambouris M, Jackson CE, Feldman GL. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Hum Mutat 1996;8:64-70.
29. Blaugrund JE, Johns MM Jr, Eby YJ, Ball DW, Baylin SB, Hruban RH, Sidransky D. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994;3:1895-7.
30. Klein I, Esik O, Homolya V, Szeri F, Varadi A. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol 2001; 170:661-6.
31. Igaz P, Patocs A, Racz K, Klein I, Varadi A, Esik O. Occurrence of pheochromocytoma in a MEN 2A family with codon 609 mutation of the RET proto-oncogene. J Clin Endocrinol Metab 2002;87:2994.
32. Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ, Ploos van Amstel HK. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Hum Genet 1996;97:11-4.
33. Oriola J, Paramo C, Halperin I, Garcia-Mayor RV, Rivera-Fillat F. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma. Am J Med Genet 1998;78:271-3.
34. Nishikawa M, Murakumo Y, Imai T, Kawai K, Nagaya M, Funahashi H, Nakao A, Takahashi M. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease. Eur J Hum Genet 2003;11: 364-8.
35. Marsh DJ, Robinson BG, Andrew S, Richardson AL, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994;23:477-9.
36. Pasini B, Rossi R, Ambrosio MR, Zatelli MC, Gullo M, Gobbo M, Collini P, Aiello A, Pansini G, Trasforini G, degli Uberti EC. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 2002;131:373-81.
37. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fekete C, Munnich A, et al. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 1995;4:1381-6.
38. Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA Jr. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 1997;14:3103-6.
39. Bae SJ, Kim DJ, Kim JY, Park SY, Choi SH, Song YD, Ki CS, Chung JH. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A. Thyroid 2006;16:609-14.
40. Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, Gangi E, Beck-Peccoz P. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003;59:156-61.
41. McMahon R, Mulligan LM, Healey CS, Payne SJ, Ponder M, Ferguson-Smith MA, Barton DE, Ponder BA. Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Hum Mol Genet 1994;3:643-6.
42. Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G. A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin Genet 1997;51:86-90.
43. Ahmed SA, Snow-Bailey K, Highsmith WE, Sun W, Fenwick RG, Mao R. Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 2005;7:283-8.
44. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-13.
45. Antinolo G, Marcos I, Fernandez RM, Romero M, Borrego S. A novel germline point mutation, c.2304 G-->T, in codon 768 of the RET proto-oncogene in a patient with medullary thyroid carcinoma. Am J Med Genet 2002;110:85-7.
46. D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:754-9.
47. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K. Prospective trial of unilateral surgery for non-hereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 2002;8:1023-8.
48. Maschek W, Pichler R, Rieger R, Weinhausel A, Berg J. A new identified germline mutation of the RET proto-oncogene responsible for familial medullary thyroid carcinoma in co-existence with a hyperfunctioning autonomous nodule. Clin Endocrinol (Oxf) 2002;5:823.
49. Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhoff M, Thanh PN, Frilling A, Klar E, Niederle B, Dralle H. RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome? Surgery 2002;132:952-9
50. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10: 2415-9.
51. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA. 1999;281:1587-8.
52. Fink M, Weinhusel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Int J Cancer 1996;69:312-6.
53. Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, Hodgson S, Clarke S, Pierotti M, Ponder BA, Bongarzone I. A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Mol Endocrinol 2006;20:1633-43.
54. Demeester R, Parma J, Cochaux P, Vassart G, Abramowicz MJ. A rare variant, I852M, of the RET proto-oncogene in a patient with medullary thyroid carcinoma at age 20 years. Hum Mutat 2001;17:354.
55. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997;82:3902-4.
56. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 2004;89:5823-7.
57. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997;82: 4176-8.
58. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 2004;89:4142-5.
59. Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:3521-6.
60. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994;91:1579-83.
61. Kitamura Y, Scavarda N, Wells SA Jr, Jackson CE, Goodfellow PJ. Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Hum Mol Genet 1995;4:1987-8.
62. Pigny P, Bauters C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerckaert JP, Porchet N. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 1999;84: 1700-4.
63. Höppner W, Ritter MM. A duplication of 12 bp in the critical cysteine-rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 1997;6:587-90.
64. Höppner W, Dralle H, Brabant G. Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia. type 2A. Hum Mutat 1998; Suppl 1:S128-30.
65. Donis-Keller H. The RET proto-oncogene and cancer. J Intern Med 1995;238:319-25.
66. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-35.
67. Cordella D, Muzza M, Alberti L, Colombo P, Travaglini P, Beck-Peccoz P, Fugazzola L, Persani L. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma. Endocr Relat Cancer 2006;13:945-53.
68. Vandenbosch K, Renard M, Uyttebroeck A, Sciot R, Matthijs G, Legius E. Medullary thyroid carcinoma in a child with a new RET mutation and a RET polymorphism. Genet Couns 2005;16: 95-100.
69. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K. Two germline missense mutations at codons 804 and 806 of the RET proto oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999; 90:1-5.
70. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997;82:3902-4.
71. Prazeres HJ, Rodrigues F, Figueiredo P, Naidenov P, Soares P, Bugatho MJ, Lacerda M, Campos B, Martins TC. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin Endocrinol (Oxf) 2006;64:659-66.
72. Dvorakova S, Vaclavikova E, Ryska A, Cap J, Vlcek P, Duskova J, Kodetova D, Holub V, Novak Z, Bendlova B. Double germline mutations in the RET proto-oncogene in MEN 2A and MEN 2B kindreds. Exp Clin Endocrinol Diabetes 2006;114: 192-6.
73. Tessitore A, Sinisi AA, Pasquali D, Cardone M, Vitale D, Bellastella A, Colantuoni V. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J Clin Endocrinol Metab 1999;84:3522-7.
74. Poturnajova M, Altanerova V, Kostalova L, Breza J, Altaner C. Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome. J Mol Med 2005;83:287-95.
75. Nunes AB, Ezabella MC, Pereira AC, Krieger JE, Toledo SP. A novel Va16481le substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma. J Clin Endocrinol Metah 2002;87:5658-61.
76. Jindrichova S, Vcelak J, Vlcek P, Neradilova M, Nemec J, Bendlova B. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 2004;183:257-65.
77. Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellim P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 2006;66:10179-87.
78. Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD. Familial medullary thyroid carcinoma and prominent comeal nerves associated with the germline V804M and V7781 mutations on the same allele of RET. J Med Genet 2001;38:784-7.
79. Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van Diest PJ, Lips CJ. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 2002;87:393-7.
80. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Hoppner W. A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 2000;108:128-32.